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ABSTRACT
PURPOSE: Evaluate the application of Hyperbaric Oxygen Therapy (HBO) in patients with Crohn’s disease (CD) refractory to
pharmacologic therapy, who developed abdominal, anorectal or skin complications.
METHODS: Fourteen selected patients with refractory CD and treated at the School of Medicine of Ribeirao Preto, University of Sao
Paulo (FMRP-USP) and at the Center of Hyperbaric Medicine, São Paulo Hospital (CEMEHI) were submitted to HBO.
RESULTS: Of the 14 patients evaluated, 11 had a satisfactory response.
CONCLUSION: HBO has shown benefits in patients with CD refractory to pharmacologic therapy.
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RESUMO
OBJETIVOS: Avaliar a aplicação da Oxigenoterapia Hiperbárica (HBO) nos pacientes com doença de Crohn (CD), refratários a
terapia farmacológica, que evoluíram com complicações abdominais, orificiais ou dermatológicas.
MÉTODOS: Catorze pacientes selecionados no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de
São Paulo e no Centro de Medicina Hiperbárica do Hospital São Paulo de Ribeirão Preto eram portadores de Doença de Crohn
refratária ao tratamento farmacológico e foram submetidos a sessões de HBO.
RESULTADOS: Dos 14 pacientes avaliados, 11 apresentaram resposta satisfatória.
CONCLUSÃO: A HBO tem demonstrado benefício nos pacientes com Doença de Crohn refratários ao tratamento farmacológico.
Descritores: Doença de Crohn. Oxigenação Hiperbárica. Complicações.
Introduction
Crohn’s disease (CD) is an idiopathic, chronic, transmural,
inflammatory disorder that can affect the whole gastrointestinal
tract1. Studies demonstrate a dysfunctional relationship between
genetic, immunological and environmental factors resulting in an
imbalance between proinflammatory and anti-inflammatory
mediators2-4. Its incidence has increased in recent decades,
especially in developed countries; and this has stimulated the
interest in novel pharmacological and surgical therapies.
The “Biological therapy” is the most advanced weapon
against the disease and it targets the TNF-alpha. TNF is a naturally
occurring cytokine involved in inflammatory and immune
responses. Several studies have demonstrated the benefits of these
medications as they provide a longer-lasting remission,
corticosteroids independence and prevention of complications
such as fistulas and stenosis5-8.
With the advent of new drugs for CD there has been a
remarkable clinical improvement as these medications seek to
control the inflammatory cascade9-13. However, even with the
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anti-TNF therapy associated or not to other immunosuppressive
drugs, there are still challenging cases refractory to medical
and surgical treatment and tissue destruction is the ultimate
result14,15.
Poor healing of the mucosa, fistulae persistence,
infectious processes and progressive stenosis are some of the
complications that can cause nutritional depletion and
immunosuppression of the patients. These factors lead to
prolonged hospitalization, systemic infections and significant
increase in morbidity and mortality16-19.
Drug optimization tends to be ineffective and surgical
intervention may be necessary20. There is a higher risk of
complication in patients with CD and it is known that correct
healing in the areas of resection is impaired by bacterial
colonization21.
Several authors advocate the use of Hyperbaric Oxygen
Therapy (HBO) as an adjuvant option in patients with refractory
disease and the results are favorable22-24. Is consists in expose the
patient in a chamber with 100% oxygen with higher pressure
(2ATA). HBO promotes increments in plasmatic partial pressures
of O2, thus enhancing tissue levels of oxygenation. It´s know that
HBO promotes healing in chronic wounds24.
The purpose of this study is to report the experience of
the authors with the utilization of HBO as adjuvant therapy in
selected cases.
Methods
Fourteen patients prospectively selected were followed
at the Division of Coloproctology in FMRP-USP and in the
CEMEHI with chronic abdominal wounds (enteric-cutaneous
fistula), perineal disease (fistulas or chronic perineal wounds) or
pyoderma gangrenosum were considered refractory to
pharmacological therapy.
The number of sessions ranged from 10-50 according to
patient’s evolution. We used a Sechrist monoplace chamber
pressurized to 2.4 ATA. The sessions lasted 2 hours and were
performed daily.
Results
Of the 14 patients studied, 6 had abdominal injuries due
to enteric-cutaneous fistula, 10 had perineal disease and 2 presented
with pyoderma gangrenosum. Eleven patients (78,5%) had a
satisfactory improvement, healing and good local control of
inflammation. Three patients (21,5%) maintained injuries and
required surgical approaches (Table 1).
Patients 
 
Abdominal 
Injury 
Perineal 
Injury 
Pyoderma 
Gangrenosum 
Number of 
Sessions 
Satisfactory 
Result 
LGM, 29 years YES YES NO 20 YES 
MAG, 45 years YES NO NO 20 YES 
SLV, 20 years NO YES NO 20 NO 
FFVM, 41 years NO YES NO 32 YES 
CPD, 41 years NO YES NO 20 YES 
RBR, 41 years YES NO YES 40 YES 
TCS, 32 years NO YES NO 40 YES 
JNAC, 52 years NO YES NO 20 YES 
LCPJ, 41 years NO YES NO 40 YES 
ACT, 35 years YES NO NO 20 YES 
JG, 38 years NO YES NO 30 YES 
MAS, 42 years NO YES NO 18 NO 
JC,  YES NO NO 20 NO 
VHLL, 49 years YES YES YES 50 YES 
TABLE 1 - Patients and results.
In the present study 11 of the 14 patients had a complete
or partial improvement of their cicatrization. The following images
show these benefits (Figures 1, 2 and 3).
FIGURE 1 - LGM, 29 years – abdominal (before and after) and perineal (before and after) disease. Before and after 20 sessions of HBO.
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FIGURE 3 - RBR, 41 years – pyoderma gangrenosum. Before and after 20 sessions of HBO.
FIGURE 2 - LCPJ, 41 years – complex anorectal fistulae. Before and after sessions of HBO.
 
 
Discussion
Even with all pharmacological advances in the
treatment of CD, many patients still present a relapsing course.
Some cases are impressively aggressive and mutilating. This
situation usually requires surgical intervention and other
measures to improve wound healing20.
Utilization of HBO in patients with CD has increased
in recent years. HBO promotes increments in plasmatic partial
pressures of O2, thus enhancing tissue levels of oxygenation.
Tissue hyperoxia increases the healing processes as it leads
to vasoconstriction and decreased edema and also stimulates
angiogenesis and proliferation of fibroblasts and collagen.
There are also some reports of increased bacteriostatic and
bactericidal effects17-23.
HBO acts directly in the inflammatory cascade and the
effect of such therapy can be explained by reduced activity of
nitric oxide synthase and inhibition of inflammatory cytokines.
It is effective in suppressing the activity of COX-2 and the stimuli
for the THF-alpha production. Vascular endothelial growth factor
(VGEF) is significantly increased with HBO25.
Conclusions
The understanding of the pathophysiology of CD has
increased in recent years as our genetic and molecular knowledge
progresses, resulting in more effective therapies. Nevertheless,
the response is not uniform among patients and progression to
complications such as extensive perineal disease may be
inevitable. HBO was initially indicated only for complex perineal
disease. Our report, as many other in the literature, expands the
traditional HBO applications and shows its efficacy in controlling
both systemic and local inflammatory activity. The benefits
become evident as the healing process advances.
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